Reviewing Alpha Tau Medical (DRTS) & Its Peers

Alpha Tau Medical (NASDAQ:DRTS – Get Rating) is one of 228 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare Alpha Tau Medical to related businesses based on the strength of its profitability, risk, valuation, analyst recommendations, earnings, dividends and institutional ownership.

Earnings and Valuation

This table compares Alpha Tau Medical and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Tau Medical	N/A	-$33.76 million	-4.62
Alpha Tau Medical Competitors	$1.13 billion	$57.96 million	-2.94

Alpha Tau Medical’s competitors have higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Alpha Tau Medical and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-32.53%	-27.99%
Alpha Tau Medical Competitors	-1,305.72%	-152.64%	-26.86%

Insider and Institutional Ownership

1.0% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 45.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by insiders. Comparatively, 14.6% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Alpha Tau Medical has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Alpha Tau Medical’s competitors have a beta of 1.39, indicating that their average share price is 39% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Alpha Tau Medical and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	0	0	3	0	3.00
Alpha Tau Medical Competitors	991	3591	7792	180	2.57

Alpha Tau Medical currently has a consensus target price of $17.67, indicating a potential upside of 488.89%. As a group, “Surgical & medical instruments” companies have a potential upside of 27.98%. Given Alpha Tau Medical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Alpha Tau Medical is more favorable than its competitors.

Summary

Alpha Tau Medical competitors beat Alpha Tau Medical on 7 of the 13 factors compared.

About Alpha Tau Medical

(Get Rating)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.